Bristol-Myers Squibb Stock Forecast for 2022 - 2025 - 2030
Updated on 09/27/2022
Bristol-Myers Squibb Stock Forecast and Price Target
If the average 2022 price target of $83.00 recently set by sixteen prominent experts for Bristol-Myers Squibb is met, there would be a potential upside of approximately 18.32% from the last closing price in September, 2022. The high estimate is $94.00, and the low is $61.00. If you're looking for information on Bristol-Myers Squibb stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
18.32% Upside
Bristol-Myers Squibb Fair Value Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's Price has grown, rising from $48.28 to $91.10 – a growth of 88.69%. In the next year, analysts believe that Fair Value will reach $93.89 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's Fair Value will decrease by 8.79%, to $83.09.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
12
|
$165.70 | $185.07 | 9.84% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$307.50 | $333.19 | 13.82% |
| ROG Stock Forecast | Roche Holding | Outperform |
18
|
CHF305.90 | CHF384.23 | 22.59% |
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$141.21 | $164.23 | 10.47% |
| PFE Stock Forecast | Pfizer | Outperform |
3
|
$43.83 | $56.27 | 20.92% |
Bristol-Myers Squibb Revenue Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's Revenue has grown, rising from $22.56B to $46.39B – a growth of 105.60%. In the next year, analysts believe that Revenue will reach $47.10B – an increase of 1.55%. By 2030, professionals predict that Bristol-Myers Squibb's Revenue will decrease by 20.45%, to $36.90B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MRK Stock Forecast | Merck | Outperform |
6
|
$86.18 | $99.57 | 16.04% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
18
|
kr741.60 | kr678.96 | 20.69% |
| DHR Stock Forecast | Danaher | Outperform |
16
|
$262.66 | $321.60 | 23.73% |
Bristol-Myers Squibb Dividend per Share Forecast for 2022 - 2025 - 2030
Bristol-Myers Squibb's Dividend per Share has grown In the last three years, rising from $1.61 to $2.01 – a growth of 24.84%. In the next year, analysts believe that Dividend per Share will reach $2.13 – an increase of 5.97%. For the next nine years, experts predict that Bristol-Myers Squibb's Dividend per Share will grow at a rate of 4.48%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
18
|
£99.33 | £136.08 | 43.33% |
| NOVN Stock Forecast | Novartis | Hold |
18
|
CHF73.98 | CHF103.75 | 20.40% |
| AMGN Stock Forecast | Amgen | Hold |
9
|
$226.87 | $246.51 | 12.40% |
Bristol-Myers Squibb Free Cash Flow Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's Free Cash Flow has grown by 149.13%, rising from $6.12B to $15.23B. For the next year, analysts predict that Free Cash Flow will reach $20.19B – an increase of 32.50%. In 2030, professionals predict that Bristol-Myers Squibb's Free Cash Flow will decrease by 2.26%, reaching $14.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic | Outperform |
18
|
$81.33 | $106.84 | 30.33% |
| SAN Stock Forecast | Sanofi | Outperform |
18
|
77.44€ | 104.66€ | 42.05% |
| GILD Stock Forecast | Gilead Sciences | Outperform |
11
|
$62.34 | $69.65 | 13.89% |
Bristol-Myers Squibb Net Income Forecast for 2022 - 2025 - 2030
Bristol-Myers Squibb's Net Income has seen impressive growth In the last three years, rising from $4.92B to $6.99B – a growth of 42.15%. In the next year, analysts believe that Net Income will reach $16.50B – an increase of 135.92%. For the next nine years, the forecast is for Net Income to grow by 90.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$686.10 | $696.64 | 10.48% |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
18
|
158.55€ | 147.51€ | 32.45% |
| MMM Stock Forecast | 3M | Hold |
16
|
$113.00 | $147.79 | 21.24% |
Bristol-Myers Squibb EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EBITDA has grown, moving from $5.87B to $20.58B – an increase of 250.70%. In the next year, analysts predict that EBITDA will jump to $21.39B – up 3.95% from the current level. By 2030, professionals believe that Bristol-Myers Squibb's EBITDA will have decreased by 32.53%, falling to $13.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GSK Stock Forecast | GSK | Outperform |
16
|
£13.25 | £16.08 | 43.02% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
48.37€ | 67.79€ | 64.36% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.42k | ¥0.00 | 31.66% |
Bristol-Myers Squibb EBIT Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EBIT has seen an increase, rising from $5.28B to $9.82B. This represents a growth of 86.09%. Analysts predict that Bristol-Myers Squibb's EBIT will increase in the upcoming year, reaching $19.38B. This would represent an increase of 97.33%. Over the next nine years, experts predict that Bristol-Myers Squibb's EBIT will grow at a rate of 54.90%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$122.31 | $149.56 | 22.64% |
| BAS Stock Forecast | BASF | Outperform |
11
|
39.81€ | 78.27€ | 38.16% |
| ILMN Stock Forecast | Illumina | Outperform |
16
|
$184.12 | $251.56 | 30.62% |
Bristol-Myers Squibb EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EPS has grown, rising from $3.98 to $7.51 – a growth of 88.69%. In the next year, analysts believe that EPS will reach $7.74 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's EPS will decrease by 8.79%, to $6.85.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen | Outperform |
11
|
$195.75 | $242.78 | 16.22% |
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$54.91 | $69.92 | 25.66% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.89k | ¥0.00 | 27.05% |